Perspective Therapeutics, Inc.
CATX Healthcare Medical Devices
Perspective Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $884,000.00, down 39.2% from fiscal 2024. In the quarter to June 2026, revenue fell 72.1%, EPS grew 24.1%, free cash flow fell 66.1% and total debt fell 3.57%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
Follow CATX
Perspective Therapeutics, Inc. (CATX) Altman Z-score
Perspective Therapeutics, Inc.'s Altman Z-score for fiscal 2025 is −0.59, in the distress zone (below 1.81).
Altman Z-score, annual
Embed this chart
Annual newest first
| Period | Altman Z-score | Change (points) |
|---|---|---|
| FY2025 | −0.59 | (1.95) |
| FY2024 | 1.37 | 2.07 |
| FY2023 | −0.70 | (7.81) |
| FY2022 | 7.11 | (8.73) |
| FY2021 | 15.84 | 22.02 |
| FY2020 | −6.18 | (2.82) |
| FY2019 | −3.36 | 7.00 |
| FY2018 | −10.36 | (14.14) |
| FY2017 | 3.78 | (8.13) |
| FY2016 | 11.91 | (6.65) |
How fiscal 2025’s score is made up
| Component | This year | Year before | Result | Points |
|---|---|---|---|---|
| Working capital / total assets | 0.45 | — | 0.54 | |
| Retained earnings / total assets | (1.25) | — | −1.76 | |
| EBIT / total assets | (0.43) | — | −1.40 | |
| Market value of equity / total liabilities | 3.39 | — | 2.03 | |
| Sales / total assets | 0.00 | — | 0.00 | |
| Altman Z-score | Distress zone | −0.59 | ||
| Z″ Variant for non-manufacturing and asset-light companies (drops the sales/assets term, uses book equity) | Distress zone | −0.38 | ||
How the Altman Z-score works
Z = 1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets (Altman, 1968). The market value of equity is the close on the last trading day of the fiscal year times weighted basic shares.
Z″ = 6.56 × working capital ÷ total assets + 3.26 × retained earnings ÷ total assets + 6.72 × EBIT ÷ total assets + 1.05 × book equity ÷ total liabilities (Altman, Hartzell and Peck, 1995), the variant for non-manufacturing and asset-light companies.
| Zone | Z | Z″ |
|---|---|---|
| Safe zone | above 2.99 | above 2.60 |
| Grey zone | 1.81–2.99 | 1.10–2.60 |
| Distress zone | below 1.81 | below 1.10 |
Not worked out for banks, insurers and REITs, whose balance sheets the model does not describe, nor when a figure is missing or there is no share price in the week to the fiscal year end.
Altman Z-score against peers
| Company | Altman Z-score |
|---|---|
| ELMD Electromed, Inc. compare | 20.3× |
| PROF Profound Medical compare | 7.3× |
| INFU InfuSystems Holdings, Inc. compare | 3.7× |
| CLPT ClearPoint Neuro, Inc. compare | 0.4× |
| QSI Quantum-Si Incorporated compare | 0.4× |
| TMCI Treace Medical Concepts, Inc. compare | −0.1× |
| CATX Perspective Therapeutics, Inc. | −0.6× |
| LAB Standard BioTools Inc. compare | −0.8× |
| TLSI TriSalus Life Sciences, Inc. compare | −11.3× |
What Altman Z-score is
The Altman Z-Score weighs working capital, retained earnings, operating profit, market value and sales against assets and debts to gauge the risk of distress.
1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets